Lyell Immunopharma, Inc. Operating Income
Lyell Immunopharma, Inc. (LYEL) reported Operating Income of -$47.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Lyell Immunopharma, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$47.34M.
- Lyell Immunopharma, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$44.26M.
- Lyell Immunopharma, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$127.64M.
- Lyell Immunopharma, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$37.25M.
- Lyell Immunopharma, Inc. operating income (loss) for fiscal 2025 was -$269.40M.
- Lyell Immunopharma, Inc. operating income (loss) for fiscal 2024 was -$358.75M.
- Lyell Immunopharma, Inc. operating income (loss) for fiscal 2023 was -$247.01M.
- Lyell Immunopharma, Inc. operating income (loss) for fiscal 2022 was -$187.06M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$47.34M 10-Q · filed 2026-08-06 | -$91.60M 10-Q · filed 2026-08-06 | -$219.24M derived: sum of 3 quarters · filed 2026-08-06 | -$256.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$44.26M 10-Q · filed 2026-05-06 | -$171.91M derived: sum of 2 quarters · filed 2026-05-06 | -$209.16M derived: sum of 3 quarters · filed 2026-05-06 | -$256.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$127.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$164.90M derived: sum of 2 quarters · filed 2026-03-12 | -$212.04M derived: sum of 3 quarters · filed 2026-08-06 | -$269.40M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$37.25M 10-Q · filed 2025-11-12 | -$84.39M derived: sum of 2 quarters · filed 2026-08-06 | -$141.76M 10-Q · filed 2025-11-12 | -$342.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$47.14M 10-Q · filed 2026-08-06 | -$104.51M 10-Q · filed 2026-08-06 | -$305.65M derived: sum of 3 quarters · filed 2026-08-06 | -$356.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$57.37M 10-Q · filed 2026-05-06 | -$258.51M derived: sum of 2 quarters · filed 2026-05-06 | -$309.02M derived: sum of 3 quarters · filed 2026-05-06 | -$360.55M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$201.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$251.65M derived: sum of 2 quarters · filed 2026-03-12 | -$303.18M derived: sum of 3 quarters · filed 2026-03-12 | -$358.75M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$50.51M 10-Q · filed 2025-11-12 | -$102.03M derived: sum of 2 quarters · filed 2025-11-12 | -$157.61M 10-Q · filed 2025-11-12 | -$217.12M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | -$51.53M 10-Q · filed 2025-08-12 | -$107.10M 10-Q · filed 2025-08-12 | -$166.61M derived: sum of 3 quarters · filed 2026-03-12 | -$225.65M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$55.58M 10-Q · filed 2025-05-13 | -$115.08M derived: sum of 2 quarters · filed 2026-03-12 | -$174.12M derived: sum of 3 quarters · filed 2026-03-12 | -$240.03M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$59.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$118.55M derived: sum of 2 quarters · filed 2026-03-12 | -$184.45M derived: sum of 3 quarters · filed 2026-03-12 | -$247.01M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$59.04M 10-Q · filed 2024-11-07 | -$124.94M derived: sum of 2 quarters · filed 2024-11-07 | -$187.50M 10-Q · filed 2024-11-07 | -$202.28M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$65.91M 10-Q · filed 2024-08-07 | -$128.46M 10-Q · filed 2024-08-07 | -$143.25M derived: sum of 3 quarters · filed 2025-03-11 | -$209.68M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | -$62.56M 10-Q · filed 2024-05-06 | -$77.34M derived: sum of 2 quarters · filed 2025-03-11 | -$143.78M derived: sum of 3 quarters · filed 2025-03-11 | -$181.04M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | -$14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$81.22M derived: sum of 2 quarters · filed 2025-03-11 | -$118.48M derived: sum of 3 quarters · filed 2025-03-11 | -$187.06M 10-K · filed 2025-03-11 |
| 2022-09-30 | -$66.44M 10-Q · filed 2023-11-07 | -$103.70M derived: sum of 2 quarters · filed 2023-11-07 | -$172.27M 10-Q · filed 2023-11-07 | -$219.81M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$37.26M 10-Q · filed 2023-08-08 | -$105.84M 10-Q · filed 2023-08-08 | -$153.38M derived: sum of 3 quarters · filed 2024-02-28 | -$202.54M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$68.58M 10-Q · filed 2023-05-04 | -$116.11M derived: sum of 2 quarters · filed 2024-02-28 | -$165.28M derived: sum of 3 quarters · filed 2024-02-28 | -$227.98M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$47.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$96.70M derived: sum of 2 quarters · filed 2024-02-28 | -$159.41M derived: sum of 3 quarters · filed 2024-02-28 | -$214.78M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$49.16M 10-Q · filed 2022-11-08 | -$111.87M derived: sum of 2 quarters · filed 2022-11-08 | -$167.24M 10-Q · filed 2022-11-08 | -$206.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$62.71M 10-Q · filed 2022-08-04 | -$118.08M 10-Q · filed 2022-08-04 | -$157.60M derived: sum of 3 quarters · filed 2023-02-28 | -$194.44M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$55.37M 10-Q · filed 2022-05-10 | -$94.89M derived: sum of 2 quarters · filed 2023-02-28 | -$131.74M derived: sum of 3 quarters · filed 2023-02-28 | -$234.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$39.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$76.37M derived: sum of 2 quarters · filed 2023-02-28 | -$178.93M derived: sum of 3 quarters · filed 2023-02-28 | -$211.94M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$36.84M 10-Q · filed 2021-11-12 | -$139.41M derived: sum of 2 quarters · filed 2021-11-12 | -$172.41M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$102.57M 10-Q · filed 2021-08-12 | -$135.57M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | -$102.09M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |